Emergent BioSolutions Inc. (NYSE:EBS) Shares Sold by Point72 Asia Singapore Pte. Ltd.

Point72 Asia Singapore Pte. Ltd. lessened its position in shares of Emergent BioSolutions Inc. (NYSE:EBS) by 88.2% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 8,401 shares of the biopharmaceutical company’s stock after selling 62,677 shares during the period. Point72 Asia Singapore Pte. Ltd.’s holdings in Emergent BioSolutions were worth $70,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Tidal Investments LLC bought a new position in Emergent BioSolutions during the first quarter worth $34,000. CWM LLC lifted its position in shares of Emergent BioSolutions by 32,706.7% in the 2nd quarter. CWM LLC now owns 4,921 shares of the biopharmaceutical company’s stock worth $34,000 after buying an additional 4,906 shares during the last quarter. Meeder Asset Management Inc. acquired a new position in shares of Emergent BioSolutions in the 2nd quarter valued at about $41,000. Price T Rowe Associates Inc. MD grew its position in shares of Emergent BioSolutions by 22.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 23,943 shares of the biopharmaceutical company’s stock valued at $61,000 after buying an additional 4,409 shares during the last quarter. Finally, Verus Capital Partners LLC acquired a new stake in Emergent BioSolutions during the second quarter worth about $68,000. Institutional investors and hedge funds own 78.40% of the company’s stock.

Emergent BioSolutions Price Performance

Shares of NYSE:EBS opened at $9.01 on Friday. The firm’s 50 day moving average is $9.38 and its two-hundred day moving average is $8.54. The firm has a market capitalization of $488.16 million, a P/E ratio of -2.20 and a beta of 1.59. The company has a current ratio of 2.88, a quick ratio of 1.47 and a debt-to-equity ratio of 1.30. Emergent BioSolutions Inc. has a 52 week low of $1.42 and a 52 week high of $15.10.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on EBS shares. Rodman & Renshaw reaffirmed a “buy” rating and set a $16.00 target price on shares of Emergent BioSolutions in a report on Friday, September 13th. StockNews.com downgraded Emergent BioSolutions from a “buy” rating to a “hold” rating in a research note on Wednesday, November 20th. Finally, Benchmark raised their target price on Emergent BioSolutions from $8.00 to $12.00 and gave the company a “buy” rating in a research note on Thursday, November 7th.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.